Biotron expands HCV trial
Thursday, 14 August, 2008
Biotron [ASX: BIT] has expanded its Phase Ib/IIa clinical trial of its BIT225 hepatitis C treatment in an effort to maximise recruitment rates.
Testing will now be conducted at a Brisbane site in addition to the planned trial at a site in NSW.
The trial will be a placebo-controlled, randomised and multi-dose study examining the safety, pharmacokinetics and antiviral activity of the treatment.
The trial should be completed by the end of the year.
BIT225 targets the p7 protein of HCV, and has shown promising results in surrogate models of HCV infection.
AusBiotech partners with Tenmile
Designed to support Australia's homegrown life sciences innovation, AusBiotech has announced...
Australian CDC issues update in wake of Ebola outbreak
After the WHO determined the outbreak of Ebola in the DRC and Uganda to be a public health...
Australia announces $7.2m diphtheria outbreak response package
To respond to the biggest diphtheria outbreak on record, support has been announced for the NT...
